HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

microsomal triglyceride transfer protein

consists of 97-kDa catalytic subunit associated with protein-disulfide isomerase; transfers triglycerides between lipid membranes; amino acid sequence in first source; do not confuse with MTP protein, lipid transfer protein, or LTP-I protein
Also Known As:
MTP triglyceride carrier; MTTP protein, human; Mttp protein, mouse; Mttp protein, rat; microsomal TG transfer protein; microsomal triglyceride transfer protein, human; microsomal triglyceride transfer protein, mouse; microsomal triglyceride transfer protein, rat
Networked: 149 relevant articles (4 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Hussain, M Mahmood: 7 articles (10/2015 - 05/2006)
2. Iqbal, Jahangir: 6 articles (10/2015 - 05/2006)
3. Davidson, Nicholas O: 5 articles (05/2014 - 11/2006)
4. Cuchel, Marina: 4 articles (01/2015 - 01/2007)
5. Fisher, Edward A: 4 articles (10/2014 - 02/2002)
6. Nakajima, Atsushi: 4 articles (05/2014 - 09/2009)
7. Tarugi, Patrizia: 3 articles (10/2015 - 01/2004)
8. Di Leo, Enza: 3 articles (10/2015 - 01/2004)
9. Wada, Koichiro: 3 articles (05/2014 - 09/2009)
10. Sassolas, Agnès: 3 articles (03/2012 - 08/2009)

Related Diseases

1. Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
2. Fibrosis (Cirrhosis)
11/01/2014 - "A polymorphism in the microsomal triglyceride transfer protein (MTP) is associated with hepatic fibrosis, and carriers showed higher levels of steatosis, higher levels of hepatitis C virus (HCV) RNA and advanced fibrosis. "
01/01/2011 - "In FLS mice which developed non-alcoholic steatohepatitis with normal feed, accumulation of hepatic lipids caused by reduced VLDL secretion progressed to hepatic inflammation and fibrosis, which was ameliorated by vector-induced hepatic expression of microsomal triglyceride transfer protein, a key molecule for VLDL secretion. "
09/01/2009 - "Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-alpha1 (PPAR-alpha1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model. "
02/01/2007 - "Preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, tumor necrosis factor alpha, transforming growth factor beta, and angiotensinogen may be associated with steatohepatitis or hepatic fibrosis or both."
11/01/2006 - "Preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, TNF-alpha, transforming growth factor-beta, and angiotensinogen may be associated with steatohepatitis and/or fibrosis."
3. Dyslipidemias (Dyslipidemia)
4. Atherosclerosis
5. Inflammation

Related Drugs and Biologics

1. Non-alcoholic Fatty Liver Disease
2. Lipoproteins (Lipoprotein)
3. LDL Receptors (LDL Receptor)
4. implitapide
5. Peroxisome Proliferators
6. Apolipoproteins
7. BMS201038
8. O(4)-methylthymidine triphosphate
9. Messenger RNA (mRNA)
10. Cholesterol

Related Therapies and Procedures

1. Fat-Restricted Diet (Diet, Fat Restricted)
2. Drug Therapy (Chemotherapy)